

**From:** [TOPMed ACC Publications](#)  
**To:** [zhangy@upmc.edu](mailto:zhangy@upmc.edu); [nouraises@upmc.edu](mailto:nouraises@upmc.edu); [gladwinmt@upmc.edu](mailto:gladwinmt@upmc.edu)  
**Cc:** [TOPMed ACC Publications](#); [Sedlazeck, Fritz](#); [Metcalf, Ginger A.](#)  
**Subject:** TOPMed Manuscript Study-Specific Approval for walk\_PHaSST  
**Date:** Thursday, December 1, 2022 10:37:38 PM  
**Attachments:** [LOA TopmedSV paper.pdf](#)

---

Good Evening, Drs. Zhang, Nourai, and Gladwin.

I am reaching out to you on behalf of the TOPMed ACC Publications Team to confirm [study-specific approval](#) for Dr. Fritz Sedlazeck's manuscript "[Structural variation across 138,134 samples in the TOPMed consortium](#)" using the walk\_PHaSST data. This manuscript has TOPMed Structural Variation Working Group Approval (see attached) and formal approval to use walk\_PHaSST data (proposal #[12856](#)).

This is a IRC/TOPMed-wide project in which Dr. Sedlazeck and his co-investigators are working as an extension of the IRC for the purposes of this research (Therefore, they fall under the IRC's umbrella with regards to data access and letters of collaboration.).

**Their draft manuscript can be found [here](#).** Given the collaborative nature of this IRC/TOPMed-wide project, Dr. Sedlazeck is asking to include two people from each study in the [author list](#) (additional authors may be recognized in banner authorship). If you are willing, **please provide contact information and affiliation for submission.**

Finally, **Dr. Sedlazeck and his co-investigators are hoping to meet an upcoming journal submission deadline.** Your attention to this matter is much appreciated.

Dr. Sedlazeck is attached to this email should you have any follow-up questions.

Best,  
*Ashley Smith on behalf of the TOPMed ACC Publications Team*

***Ashley S. Smith, MPH, MLT(ASCP)***

*WESTAT | Public Health & Epidemiology Practice*

*o: 240-314-2344*

*c: 678-596-6467*

[AshleySmith@westat.com](mailto:AshleySmith@westat.com)